Editorial

• Volume 8 Number 10 October 2007

Conference reports

• BHIVA Autumn conference, 11-12 October 2007, London

• Audit of treating naïve patients showed basic UK guidelines not followed in over 25% patients; 60% patients start with a CD4 count <200 cells/mm3

Antiretrovirals

• Atripla approved in Europe as switch option for suppressed patients

• Maraviroc approved in Europe for treatment-experienced CCR5-tropic patients

• Paediatric formulation of fosamprenavir approved in Europe

• Raltegravir approved in the US

• EMEA recommends reinstating license for Roche’s nelfinavir

• Roche withdraw application for Biojector needle-free option for T-20

PMTCT and maternal health

• Pregnancy shows a positive impact on HIV disease progression

• African infants CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine prophylaxis

• Low rates of mother to child transmission in the DREAM and MTCT-Plus programmes

Women's health

• Antiretroviral drug exposure in the female genital tract

• Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women

• Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV Study

Paediatric care

• Risk factors for early mortality for children receiving divided adult fixed dose combination tablets in Malawi

Hepatitis coinfection

• Risk of antibody negative HCV infection in four US HIV cohorts: risk linked to IDU, elevated ALT and low CD4 count

Treatment strategies

• Current or former injecting drug use is not related to earlier switch or discontinuation of HAART compared to non-IDU patients since 1999

Treatment access

• Donor governments pledge record amounts to the Global Fund

• Survival of HIV-positive IDUs in the era of HAART

Vaccines and microbicides

• Merck HIV vaccine trial halted by DSMB for lack of efficacy

On the web

• Free full text articles

• Conference abstracts and presentations

PDFs

• Volume 8 Number 10 October 2007 PDF